Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 376.19% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 08/23/2023 | 355.78% | EF Hutton | → $6.7 | Assumes | → Buy |
| 08/16/2023 | 716.33% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 355.78% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 355.78% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 852.38% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 355.78% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 1056.46% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 355.78% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 355.78% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 1396.6% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 36.05% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 36.05% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 70.07% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 36.05% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 240.14% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 444.22% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 376.19% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/27/2023 | 376.19% | 拉登堡塔爾曼 | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/23/2023 | 355.78% | EF Hutton | → 6.7 美元 | 假設 | → 購買 |
| 08/16/2023 | 716.33% | 查丹資本 | 14 美元 → 12 美元 | 維護 | 買 |
| 06/26/2023 | 355.78% | EF Hutton | → 6.7 美元 | 重申 | 購買 → 購買 |
| 05/25/2023 | 355.78% | EF Hutton | → 6.7 美元 | 假設 | → 購買 |
| 05/11/2023 | 852.38% | 查丹資本 | 17 美元 → 14 美元 | 維護 | 買 |
| 04/19/2023 | 355.78% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 04/19/2023 | 1056.46% | 查丹資本 | 22 美元 → 17 美元 | 維護 | 買 |
| 02/15/2023 | 355.78% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 355.78% | EF Hutton | → 6.7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/22/2022 | 1396.6% | 查丹資本 | $2 → 22 美元 | 維護 | 買 |
| 08/16/2022 | 36.05% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 買 |
| 02/09/2022 | 36.05% | BTIG | 5 美元 → 2 美元 | 維護 | 買 |
| 2021 年 12 月 20 日 | 70.07% | 查丹資本 | 8 美元 → 2.5 美元 | 維護 | 買 |
| 2021 年 12 月 16 日 | 36.05% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 9 月 15 日 | 240.14% | BTIG | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 4 月 9 日 | 444.22% | 查丹資本 | 7 美元 → 8 美元 | 維護 | 買 |
| 2020 年 5 月 6 日 | 376.19% | 查丹資本 | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet Biotherapeutics（SONN）的目標價格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Ladenburg Thalmann on November 27, 2023. The analyst firm set a price target for $7.00 expecting SONN to rise to within 12 months (a possible 376.19% upside). 10 analyst firms have reported ratings in the last year.
拉登堡·塔爾曼於2023年11月27日公佈了Sonnet BioTherapeutics（納斯達克股票代碼：SONN）的最新目標股價。該分析公司將目標股價定爲7.00美元，預計SONN將在12個月內升至12個月內（可能上漲376.19％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
分析師對Sonnet Biotherapeutics（SONN）的最新評級是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Ladenburg Thalmann, and Sonnet BioTherapeutics initiated their buy rating.
Sonnet BioTherapeutics（納斯達克股票代碼：SONN）的最新分析師評級由拉登堡·塔爾曼提供，Sonnet BioTherapeutics啓動了買入評級。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Sonnet BioTherapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Sonnet BioTherapeutics的最新評級是在2023年11月27日公佈的，因此您應該預計下一個評級將在2024年11月27日左右公佈。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析師對 Sonnet BioTherapeutics (SONN) 的評級正確嗎？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a initiated with a price target of $0.00 to $7.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $1.47, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Sonnet BioTherapeutics（SONN）評級是啓動的，目標股價爲0.00美元至7.00美元。Sonnet BioTherapeutics（SONN）目前的交易價格爲1.47美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。